Anzeige
Mehr »
Login
Samstag, 02.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Technischer Ausbruch: Diese Kupferaktie ist in den letzten 52 Wochen um 300 % gestiegen! Der Durchbruch läuft!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DYY7 | ISIN: SE0009997018 | Ticker-Symbol: 4H3A
Frankfurt
01.11.24
08:04 Uhr
34,080 Euro
+0,280
+0,83 %
Branche
Elektrotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
HMS NETWORKS AB Chart 1 Jahr
5-Tage-Chart
HMS NETWORKS AB 5-Tage-Chart
RealtimeGeldBriefZeit
33,46033,76013:04
33,50033,78001.11.
GlobeNewswire (Europe)
298 Leser
Artikel bewerten:
(1)

HMS Networks AB: Resolutions at the Annual General Meeting in HMS Networks

HMS Networks AB (publ) held its Annual General Meeting on April 23, 2024. The Meeting resolved in favour of all matters in accordance with the proposals of the Board of Directors and the Nomination Committee. The main contents of the most important resolutions are described below.

ALLOCATION OF EARNINGS
The Annual General Meeting resolved to approve the Board's proposed dividend of SEK 4.40 per share. The record date for the dividend was set to be April 25, 2024. The dividend is expected to be distributed by Euroclear Sweden on April 30, 2024.

ADOPTION OF THE INCOME STATEMENT AND BALANCE SHEET AND DISCHARGE FROM LIABILITY
The Annual General Meeting resolved to adopt the income statement and balance sheet for HMS Networks AB and the group as presented by the Board. The Board and the CEO were discharged from liability for the 2023 financial year.

ELECTION OF BOARD MEMBERS AND AUDITORS AND DETERMINATION OF FEES
The Annual General Meeting resolved in accordance with the Nominating Committee's proposals, namely:

  • that six (6) Board members should be elected without any deputies,
  • that one (1) registered public accounting firm should be elected as auditor,
  • that Charlotte Brogren, Anders Mörck, Cecilia Wachtmeister, Niklas Edling and Anna Kleine should be re-elected as Board members and to elect Johan Stakeberg as new Board Member,
  • that Charlotte Brogren should be re-elected as Chairman of the Board,
  • that Öhrlings PricewaterhouseCoopers AB, with Johan Palmgren as auditor in charge, should be re-elected as auditor,
  • that the fees to the Board members should amount to a total of SEK 2,345,000, of which SEK 795,000 should be paid to the Chairman of the Board and SEK 310,000 to each other Board member, and that fee for work in the Audit Committee should amount to SEK 155,000 to the Chairman and SEK 80,000 to each other member in the Audit Committee, and that no fees should be paid for work in other committees.

BOARD'S REMUNERATION REPORT
The Annual General Meeting approved the Board's remuneration report.

GUIDELINES FOR REMUNERATION TO SENIOR EXECUTIVES
The Annual General Meeting resolved, in accordance with the Board's proposal, on guidelines for remuneration to senior executives. In relation to the previous guidelines, the new guidelines entails that senior executives shall be able to receive an annual variable cash remuneration amounting to a maximum of 80 percent of the fixed cash salary, compared to previously 50 percent of the fixed cash salary, and a long-term variable cash bonus (LTI bonus) amounting to a maximum of 40 percent of the fixed cash salary each respective year in the measurement period, compared to
previously 50 percent of the fixed cash salary per the last year in the measurement period, with the adjustment that only one LTI program may be ongoing at a time. In addition, the provision of pension premiums for other senior executives (other than the CEO) has been adjusted to adapt to the new income cap for pensionable income of 30 income base amounts from ITP1.


AUTHORISATION OF THE BOARD TO RESOLVE ON NEW SHARE ISSUES
The Annual General Meeting resolved, in accordance with the Board's proposal, to authorise the Board to resolve on new share issues of such number of shares that corresponds to a maximum of 10 per cent of the company's share capital to enable the company to finance or carry out, in whole or in part, acquisitions of companies.

IMPLEMENTATION OF SHARE SAVING PLAN 2025-2028 AND HEDGING ACTIVITIES TO ENABLE DELIVERY OF SHARES WITHIN THE PROGRAM
The Annual General Meeting resolved, in accordance with the Board's proposal, to implement a performance-based share saving plan, Share Saving Plan 2025-2028. The program is addressed to all employees and comprise a maximum of 100,000 shares. In order to enable the company's delivery of shares to the participants in the program, the Annual General Meeting further resolved, in accordance with the Board's proposal, to authorise the Board to repurchase a maximum of 100,000 of the company's own shares and to transfer the repurchased shares to the participants in the program.

For more information, please contact:
Staffan Dahlström, CEO HMS, +46 (0)35 17 29 01
Joakim Nideborn, CFO HMS, +46 (0)35 710 6983

HMS Networks AB (publ) is a market-leading provider of solutions in Industrial Information and Communication Technology (Industrial ICT) and employs over 1 200 people. Local sales and support are handled through over 20 sales offices all over the world, as well as through a wide network of distributors and partners. HMS reported sales of SEK 3,025 million in 2023 and is listed on the NASDAQ OMX in Stockholm in the Large Cap segment and Telecommunications sector.

Attachment

  • HMS Bulletin from Annual General Meeting 2024 (https://ml-eu.globenewswire.com/Resource/Download/c78fec09-a982-499a-a581-b4d7af38f426)

© 2024 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.